लोड हो रहा है...
Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of advanced differentiated thyroid carcinoma (DTC). Resistance to sorafenib may appear under treatment and may be associated with increased aggressiveness of the neoplasia. The present study reports the case of a 65-year-old male...
में बचाया:
| में प्रकाशित: | Oncol Lett |
|---|---|
| मुख्य लेखकों: | , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
D.A. Spandidos
2017
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5530175/ https://ncbi.nlm.nih.gov/pubmed/28781658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6395 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|